Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Find AGA's NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.
gastro. org. Scan this QR code to be taken directly to the website. Nonalcoholic fatty liver …

Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions worldwide.
NAFLD and type 2 diabetes mellitus (T2DM) are known to frequently coexist and act …

Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …

Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

OBJECTIVE Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver
fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 …

Initially a condition that received limited recognition and whose clinical impact was
controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic …